TOP TEN perturbations for NM_000350 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000350
Selected probe(set): 210082_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000350 (210082_at) across 5339 perturbations tested by GENEVESTIGATOR:

retina pigment epithelium study 2 (fetal) / retina pigment epithelium study 1 (fetal)

Relative Expression (log2-ratio):-3.6319237
Number of Samples:12 / 6
Experimental retina pigment epithelium study 2 (fetal)
Human cultured fetal retina pigment epithelium samples obtained at gestation age between week 16-18.
Control retina pigment epithelium study 1 (fetal)
Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18.

lung adenocarcinoma study 6 (EML4-ALK) / adjacent lung tissue

Relative Expression (log2-ratio):2.4138489
Number of Samples:8 / 20
Experimental lung adenocarcinoma study 6 (EML4-ALK)
Primary tumor sample from patients with stage II adenocarcinoma carrying the EML4-ALK-fusion.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

lung adenocarcinoma study 5 (EML4-ALK) / adjacent lung tissue

Relative Expression (log2-ratio):2.374136
Number of Samples:3 / 20
Experimental lung adenocarcinoma study 5 (EML4-ALK)
Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

atopic dermatitis study 20 (lesional; placebo; baseline) / normal skin tissue

Relative Expression (log2-ratio):-2.277567
Number of Samples:6 / 2
Experimental atopic dermatitis study 20 (lesional; placebo; baseline)
Lesional skin biopsies isolated from patients with atopic dermatitis before placebo treatment (at baseline). Adult patients (both males and females; ?18 years of age) with moderate to severe AD (documented for ? 12 months) were enrolled into study. Patients met Hanifin and Rajka criteria for AD at screening. They had AD that was not adequately controlled by a stable regimen (?4 weeks) of topical corticosteroids or topical calcineurin inhibitors within 6 months of screening, or was considered inappropriate for topical therapy because of side effects or safety risks. Further patients' characteristics: AD-affected body surface area >10%, EASI score >12, and sPGA-A score >3. Patients were stratified by geographic region (North America and Japan) and within region. Exclusion criteria: a) significant or major uncontrolled disease; b) active or history of incompletely treated tuberculosis; c) history of malignancy within the past 5 years (except treated/cured squamous cell or basal cell in situ carcinomas or cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within 5 years prior to screening); d) unstable asthma; e) significant infection within 2 weeks of screening; f) active skin infection; g) use of phototherapy or systemic immunosuppressive drugs within 4 weeks; h) use of interferon-gama within 12 weeks; i) use of biologics within 12 to 24 weeks of baseline.
Control normal skin tissue
Skin tissue biopsies obtained from control subjects.

lung adenocarcinoma study 6 (EGFR mut) / adjacent lung tissue

Relative Expression (log2-ratio):2.13546
Number of Samples:24 / 20
Experimental lung adenocarcinoma study 6 (EGFR mut)
Primary tumor sample from patients with stage II adenocarcinoma carrying an EGFR mutation.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

rhegmatogenous retinal detachment study 1 / normal retina tissue

Relative Expression (log2-ratio):-2.0177393
Number of Samples:19 / 17
Experimental rhegmatogenous retinal detachment study 1
Retina tissue samples from patients with retinal detachment obtained by vitrectomy.
Control normal retina tissue
Postmortem retina tissue samples from healthy patients without any diseases of the eye.

lung adenocarcinoma study 5 (EGFR mut) / adjacent lung tissue

Relative Expression (log2-ratio):1.9397001
Number of Samples:103 / 20
Experimental lung adenocarcinoma study 5 (EGFR mut)
Primary tumor sample from patients with stage I adenocarcinoma carrying an EGFR mutation.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

hair follicle keratinocyte study 1 (CD200-/CD49+) / hair follicle keratinocyte study 1 (CD200+/CD49+)

Relative Expression (log2-ratio):-1.7958546
Number of Samples:3 / 3
Experimental hair follicle keratinocyte study 1 (CD200-/CD49+)
Primary hair follicle keratinocytes sample negative for CD200 and positive for CD49.
Control hair follicle keratinocyte study 1 (CD200+/CD49+)
Primary hair follicle keratinocytes sample positive for CD200 and CD49.

retina pigment epithelium study 1 (adult) / retina pigment epithelium study 1 (fetal)

Relative Expression (log2-ratio):1.628356
Number of Samples:2 / 6
Experimental retina pigment epithelium study 1 (adult)
Postmortem human native retina pigment epithelium samples from adult individuals.
Control retina pigment epithelium study 1 (fetal)
Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18.

lung adenocarcinoma study 5 (EGFR/K-RAS/ALK -) / adjacent lung tissue

Relative Expression (log2-ratio):1.6222057
Number of Samples:48 / 20
Experimental lung adenocarcinoma study 5 (EGFR/K-RAS/ALK -)
Primary tumor sample from patients with triple-negative stage I adenocarcinoma of the lung. The patients were not carrying any mutation in the EGFR, K- RAS or ALK gene.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.